⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Journal of Pain Research

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States

Gary Berman Alexandra Thiry Robert Croop

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the safety and tolerability of rimegepant 75 mg for the acute treatment of migraine in participants concurrently using a preventive migraine medication.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Berman et al. (2024) studied this question.

synapsesocial.com/papers/68e6c316b6db6435876418ed https://doi.org/10.2147/jpr.s453937

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trialsRCT · 2026 · 2 citations
2RIMEGEPANT AS A NOVEL THERAPEUTIC OPTION FOR MIGRAINE: A SYSTEMATIC REVIEW OF SAFETY AND TOLERABILITYSystematic Review · 2026
3A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine2024 · 48 citations
4Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study2024 · 8 citations
5Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial2024 · 27 citations